Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. Falchi L, Sureda A, Leppa S, Vermaat JS, et al. Blood 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.

Read + Share

Amedeo Smart

Independent Medical Education

Falchi L, Sureda A, Leppa S, Vermaat JS, et al. Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. Blood 2025 Sep 8:blood.2025029909. doi: 10.1182/blood.2025029909.
PMID: 40920572